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The role of naringin on streptozotocin-induced diabetic nephropathy was investigated. Male 
Wister rats (200-300 g) were divided into six groups (n=7). Group A was treated with a 
vehicle (0.2 ml of 0.1M citrate buffer pH4.5) by a single intraperitoneal injection (IP) and 3.0 
ml/kg/BW of distilled water and group B was treated naringin (50 mg/kg/BW) daily. Groups 
C, D, E and F were rendered diabetic by a single IP of STZ (60 mg/kg/BW) in 0.1M citrate 
buffer (pH4.5). Diabetes was confirmed after 2 days (48 hours). Group C was treated with 
subcutaneous insulin (4 U/kg/BW) twice a day while groups D and F were treated with 
naringin (50 mg/kg/BW) and ramipril (20 mg/kg/BW) which is the drug that is currently used 
to treat diabetic nephropathy orally, daily, respectively. On day 55, 24-hours urine samples 
were collected and on day 56 rats were sacrificed; blood samples were collected by cardiac 
puncture and kidney and liver samples were excised and snap-frozen in liquid nitrogen for 
further analysis.  
Diabetic groups (C, D, E and F) showed significant (p<0.001) hyperglycemia, weight loss, 
polydipsia, polyuria, impaired glucose tolerance and low fasting plasma insulin compared to 
the controls. Treatment with naringin improved weight loss, polydipsia, fasting plasma 
glucose and fasting plasma insulin. Naringin decreased fasting blood glucose but did not 
improve glucose intolerance and it significantly (p<0.001) improved fasting plasma insulin 
compared to diabetic control. Furthermore, non-treated diabetic groups significantly 
(p<0.001) showed elevated plasma malondialdehyde (MDA) and reduced superoxide 
dismutase (SOD) activities compared to the controls. Naringin further reduced renal lipid 
peroxidation and increased SOD activities in diabetic rats. Moreover, naringin reversed 
electrolytes retention and also increased glomerular filtration rate in diabetic rats.  
Naringin therefore ameliorates some aspects of diabetic nephropathy (GFR, serum and urine 
electrolytes) by reversing oxidative stress associated with DN.  
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                                              CHAPTER 1 
1.0 Introduction and literature review 
1. 1 Diabetes Mellitus Epidemiology and Prevalence 
Diabetes was estimated in 2013 to affect 382 million people globally with the incidence of 
8.3% (IDF, 2009) and  type 2 diabetes making up about 90-95% of the cases (Tiwari and 
Madhusudana et al., 2002) whereas type1 diabetes makes up to 5-10% (Raskin and Mohan, 
2010). Diabetes has been ranked as a third commonest chronic diseases in the world (Fradkin, 
2012) yet many people with diabetes are estimated to be undiagnosed (IDF, 2013). 
Even though diabetes is common in developed countries, there is an increase in prevalence 
rate in Asia and Africa (Wild et al., 2004) with highest mortality rates (IDF, 2013).  
Environmental and genetic factors play an important role in the development of diabetes in 
varying populations. In South Africa it has been estimated that millions of people will suffer 
from diabetes due to sedentary lifestyles, urbanization and lack of physical activities 











1.2 Diabetes Mellitus definition and classification 
Diabetes is a metabolic disorder characterized by dyslipidemia and glucose intolerance. It is 
an increasingly prevalent condition that contributes to the increased cardiovascular morbidity 
and mortality (Formiguera and Canton, 2004). Chronic kidney diseases in patients with 
diabetes add to the morbidity and mortality. There are two major types of diabetes mellitus; 
Insulin dependent diabetes (Type 1) and Non-Insulin dependent diabetes (Type 2) (Alberti et 
al., 1998).  
 
1.2.1 Type 1 Diabetes (Insulin Dependent Diabetes Mellitus) IDDM 
 
Type 1 diabetes is autoimmune mediated destruction of pancreatic β-cells. The dendritic cells 
and macrophages in the pancreatic islets process autoantigens and present them to 
autoreactive CD4+ T cells. CD4+ T cells secret cytokines which can activate β cell-specific 
cytotoxic T cells (CD8+) which further activate macrophages and other T cells leading to  
beta cells destruction ultimately absolute insulin deficiency which predisposes individuals to 
ketoacidosis  (Lambert et al., 2004). Type 1 usually develops in young children and teenagers 
(Devendra et al., 2004). It has been found that the Human leukocyte antigen chromosome 6 is 
a genetic portion that is linked with IDDM (Anjos and Polychronakos, 2004) however, it can 









1.2.2 Type 2 Diabetes (Non-Insulin Dependent Diabetes Mellitus) NIDDM 
The pancreas produces insulin but skeletal muscle cells are resistant to it leading to insulin 
resistance (American Diabetes Association, 2005). More than 90% of diabetic individuals 
have type 2 diabetes mellitus (T2DM), a consequence of a sedentary lifestyle and lowered 
beta-cell mass and genetic predisposition, it is often diagnosed after metabolic dysfunctions 
have manifested in multiple organ systems. Insulin resistance leads to hyperglycaemia which 
gives rise to several micro-vascular and macro-vascular complications such as diabetic 
nephropathy, dyslipidemia, obesity and generation of reactive oxygen species in tissues and 
of advanced glycation products (Jakus and Rietbrock, 2004). However, pancreas lacks the 
defence system against reactive oxygen species generated by free radicals hence it is 
susceptible to oxidative damage due to the absence of glutathione peroxidase-1 gene (Elbein, 
2002). In this regard, dyslipidemia is initiated by insulin resistance which activates the 
activity of lipoprotein lipase (LPL) in adipocytes. The lipoprotein lipases that catalyses 
release of free fatty acids (FFA) which are taken up by hepatocytes leading to production of 
triglycerides. Triglycerides then stimulate production of very low density lipoproteins 










1.3 Diabetes mellitus complications 
Diabetes mellitus complications are macrovascular (atherosclerosis and coronary heart 
diseases) and microvascular complications (diabetic nephropathy, retinopathy and 
neuropathy). These complications are as a result of multiple factors intertwined together 














Figure 1: Pathophysiological significance of RAS, AGEs, Polyol, oxidative stress and PKC 
activation in diabetes (Courtesy of Daisuke Koya et al, 2003). 
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1.3.1 Advanced glycation end products (AGEs) 
Advanced glycation end- products are formed by the non-enzymatic reaction of reducing 
sugars, ascorbate and other carbohydrates with amino acids, lipids and nucleic acids. AGEs 
have been demonstrated to have wide range of chemical, cellular and tissue effects that are 
implicated in the development of diabetic complications (Magri and Fava. 2009). AGEs 
formation occurs continually in the body and is accelerated in diabetes however, external 
factors such as smoking of tobacco (Nicholl and Bucala, 1998) and western diet (Peppa et al, 
2002) have been reported to contribute to AGE formation. Peppa (2003) reported that 10% 
AGEs formed from exogenous factors is absorbed in the gastrointestinal tract and delivered 
into the liver and tissue but only 1/3 is excreted in the urine while the remaining is involved 
in AGE derived diabetes complications (Cai et al., 2002 and Vlassara et al.,2002). 
 
Recent studies, however, demonstrate that interactions of AGE modified proteins with 
different AGE-receptor complexes not only serve to degrade AGE-proteins, but also activate 
signal transduction pathways. AGEs induce the synthesis and release of cytokines and growth 
factors that might initiate tissue repair and protein turnover but also contribute to the 
development of vascular disease and diabetic complications (Forbes et al, 2002 and Kelly et 
al, 2001). In addition, AGEs also react with AGE-specific receptors; activate NADPH 
oxidase leading to increased formation of reactive oxygen species (ROS) and inflammation. 
Furthermore, AGE also interact with the renin-angiotensin system, which is another potential 







1.3.2 Renin-angiotensin system (RAS) 
In diabetes, renin levels are increased and it has been suggested that it plays a huge role in 
pathogenesis of diabetic nephropathy. Renin and prorenin receptor are suggested to be 
involved in the development and progression of kidney disease by enhancing the renal 
production of inflammatory cytokines which lead to renal cell loss (Kreisberg et al, 1994). 
Renin produces angiotensin I from angiotensinogen after which, it is cleaved by angiotensin-
I-converting enzyme (ACE) to release angiotensin II, a potent vasoconstrictor. Ang II has 
harmful effects on the kidney; it increases the expression of inflammatory cytokines and 
tubular growth factors hence inducing podocytes injury in the tubules (Kreisberg et al., 
1994). Increased renin elevates the expression of angiotensinogen gene in proximal tubule 
cells hence inducing podocytes injury via Ang II receptor gene (Klinik für Innere et al., 
2006). Ang II is also documented to stimulate the synthesis of VEGF in podocytes through 
p38 mitogen-activated protein kinase (p38 MAPK) pathway (Kang et al., 2006).  
(Rabelink, Bakris, 1992) reported that angiotensinogen influences glomerular filtration rate 
by interacting with autocrine factors such as superoxide and nitric oxide (NO) which is a 
potent oxidant (peroxynitrite) when it interacts with superoxide.  NO is unstable, it can be 
easily converted to nitrite and its activation by ROS may lead to mesenchymal proliferation, 
which is an early and characteristic lesion of diabetic nephropathy (Freeman, 1993). 
Moreover Ang II also mediates reactive oxygen species production by activating NADPH 
oxidase (James and Soweres, 2002). NADPH oxidase is a key mediator of podocytes 
apoptosis and subsequent diabetic glomerulopathy in vivo, thus mechanistically linking 
hyperglycemia, ROS, podocytes apoptosis, podocytes depletion, and diabetic nephropathy 





1.3.3 Oxidative stress  
Oxidative stress occurs when production of reactive oxygen species (ROS) as a result of free 
radicals production exceeds local antioxidant capacity (180 to 200 mV) (Trachootham et al., 
2009). Reactive oxygen species mediate many negative biological effects, including 
peroxidation of cell membrane lipids, oxidation of proteins, renal vasoconstriction and 
damage to DNA.  ROS are unstable molecules as a result of the presence of unpaired 
electrons in their molecular structure; undergo a series of interaction with biological 
macromolecules such as proteins, lipids, and DNA (Bayir, 2005).  
ROS have been reported to be highly involved in the pathogenesis of diabetes-associated 
vascular complications (Robertson et al., 2003; Wang et al., 2011). Elevated glucose 
increases the production of superoxide by mitochondrial electron transport chain with the 
help of the enzyme NADPH oxidases (Saleem et al., 2001). Glucose is reduced to sorbitol at 
the expense of reduced nicotinamide adenosine dinucleotide phosphate (NADPH) by the 




















Figure 1: Generation of oxygen reactive species through polyol pathway. (Courtesy of 
Cumbie and Heemayer, 2007). 
Advanced Glycation End- products (AGEs) leads to the production of ROS through Protein 
Kinase C-depended activation of NAD(P)H oxidase in smooth muscle cells and endothelial 
cells . AGEs alter normal protein function by modifying the structure and ultimately the 
function of the protein. Protein modification leads to disruption in redox homeostasis. 
Disruption in redox homeostasis leads to an excessive generation of ROS leading to an 
increase in oxidative stress.  
The accumulation of AGEs stimulates the release of AGEs proteins which bind to AGE 
receptors (RAGE) thereby inducing generation of free radicals.  An increase in glucose 
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uptake leads to overproduction of electron donors (NADH and FADH2) from stimulated 
glycolysis and tricarboxylic acid cycle (Wautier et al., 2001).  
 
It is hypothesized that hyperglycemia increases NADH/NAD+ ratio in cell production and 
NADH is the main electron donor to the mitochondrial electron transport chain. Therefore 
antioxidants are expected to prevent damage of mitochondria by reducing reactive oxygen 
species and their role in diabetes complications has been evaluated (Nishikawa et al., 2002). 
Using antioxidant supplements may have chemoprotective effects in diabetes (Oberley, 
1998). There are two types of antioxidants; enzymatic antioxidants (catalase, superoxide 
dismutase and glutathione peroxidase) and non-enzymatic antioxidants (Vitamin C and E and 
reduced glutathione). In diabetic state both types of antioxidants are supressed (Bonnefont-
Rousselot et al., 2000, Martim et al., 2003 and Johansen et al., 2005). Glycation impairs the 
antioxidant effect by inactivating the antioxidant enzymes superoxide dismutase in particular 
(Arali et al., 1987). Cu/Zn-SOD resolves O22 into H2O2 and O2, whereas catalase (CAT) and 
glutathione peroxidase (GSH-Px) catalyze the reduction of H2O2 to HO+O2. 
 
1.3.4 Protein Kinase C activation 
Protein Kinase C mediates diverse and important cellular functions; it has a catalytic and a 
regulatory region in its structure. Protein Kinase C has 11 isoforms, which are activated in the 
glomeruli of diabetic rats and their activation leads to upregulation of vascular endothelial 
growth factors (VEGF) in mesangial cells. The activation of PKC-β induces renal 
dysfunction by increasing tubular growth factor beta (TGF-β) and connective growth factor 
(CGF) (Aiello et al., 1994). Ishii et al, 1996 and Koya et al., (1997) reported that the 
treatment of the activated PKC-β with PKC-β inhibitor ameliorated an increase in the urinary 
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albumin excretion and the structure of the glomeruli (mesangial expansion and extracellular 
matrix) was restored as well by the treatment).  
 
It is also noted by Ishii et al, (1996) that the ruboxistaurin (PKC-β inhibitor) reduced 
albuminuria and maintain a glomerular filtration rate for 1 year in type 2 diabetic patients 
with nephropathy.  Activation of these factors leads to the accumulation of extracellular 
matrix proteins in the glomeruli and cell injury as well as apoptosis of the glomerulus cells 
(podocytes) (Aiello et al., 1994).  
 
1.4 Macrovascular complications 
1.4.1 Atherosclerosis  
In diabetes, AGE/RAGE interaction is accelerated leading to atherosclerosis and 
cardiovascular diseases. Increased AGEs modify low density lipoproteins (LDLs) in diabetic 
patients and is associated with increased inflammation, endothelial activation and 
permeability which increase local oxidative stress and LDL oxidation. Oxidation of LDL 
particles result in accumulation of endothelial walls of arteries and macrophages and T-
lymphocytes proliferation is stimulated (Michael and Owler, 2008). Stimulation of 
macrophages and T-lymphocytes proliferation further induce proliferation of smooth muscles 
in arterial walls. This process results in the formation of lipid rich- atherosclerotic lesions 
which result in vascular infarction (Boylee, 2007). The increased expression of RAGE in 
macrophages of vulnerable atherosclerotic plaques from diabetes patients, and their co-
localization with the inflammatory markers COX-2 and MMPs, support their potential 




1.4.2 Cardiovascular Diseases  
 
Although cardiovascular diseases (hypertension, Ischemic heart diseases and 
cardiomyopathy) are not specific to diabetes, they are more prevalent among patients with 
diabetes than among those without diabetes (Stemlar et al., 1993). Diabetes is associated with 
alterations in lipid profiles (Pushparaj et al., 2007). Changes in concentrations of plasma 
lipids including cholesterol and lipoprotein are complications frequently observed in patients 
with diabetes mellitus and certainly contribute to the development of coronary heart disease. 
Dyslipidemia has a strong co- relation with cardiovascular disease; it is a risk factor of CVD 
(Ford et al., 2009).  Moreover, atherosclerosis causes CVD by restricting the blood flow to 
the heart. Type 1 diabetes, however, it is often associated with coronary heart disease. 
Ischemic heart disease seen in type 1 diabetes leads to higher mortality in the general 
population. Different therapeutic agents have been developed over the years in trying to 
combat such complications.  
 
1.5 Microvascular complications 
Hyperglycemia gives rise to reactive oxygen species thus leading to oxidative stress, activates 
Protein Kinase C, renin-angiotensin aldosterone system, accumulation of nonenzymatally 
glycosilation of proteins products advanced glycation end products (AGE) and acceleration 
of Polyol pathway (Figure 3). All these, result in the activation of the vascular endothelial 
growth factors (VEGF), tubular growth factor beta (TGF-β), tumor necrosis factor alpha 
(TNF-α) and interlukins (IL) 1, 6 and 18. Vascular endothelial growth factor (VEGF) is 
known to be primarily involved in neoangiogenesis and increased endothelial permeability. 
These factors converge and promote glomerular and tubular fibrogenesis (Wolf and Ziyadeh 
1999).   
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1.5.1 Diabetic retinopathy (DR) 
DR is a diabetic complication that leads to visual impairment and blindness. The 
microvasculature of the retina is damaged, the blood vessels swell and leak fluid, and if not 
prevented, new vessels start to grow, and ultimately lead to the detachment of the retina 
(Sharma et al., 2005). The blood vessels of retina have tight junctions that protect them from 
leaking, but sustained high glucose damages the tight junctions and the vessels become leaky 
allowing fluid or blood to seep into the retina, thus resulting in the swelling of the retina 
(Bhavsar et al., 2006). Advanced Glycation End-products precursors and PKC activation 
induce retinal vessel wall thickening and growth arrest and retinal apoptosis of pericytes 
(Kowluru, 2005). Pericytes apoptosis is a key factor in retinopathy; it triggers endothelial 
activation of dysfunction which results in neoangiogenesis via activation of vascular 
endothelial growth factors. Moreover, accumulation of polyols results in elevation of 
intracellular sorbitol which causes damage in vascular cells causing retinal and neural 
damage in diabetes. AGEs are involved in the pathogenesis of diabetic retinopathy by altering 
small vessel wall integrity and structure and by inducing cytokines, growth factors and 
increased oxidative stress (Yamagishi et al., 2002). 
 
1.5.2 Diabetic Neuropathy (DN) 
DN is characterized by impaired wound healing due to a decrease in oxygen in tissues 
because of glycated haemoglobin and altered immune system. It is associated with increased 
necrosis, impaired wound healing and loss of pain perception (Huijberts et al., 2008). AGEs 
are implicated to be involved in loss of pain perception; they induce the expression of 
inflammatory genes resulting in neurologic dysfunction and altered pain sensation (Herold et 
al., 2007). AGEs modify axonal cytoskeleton tubulin, neurofilament and actin leading to 
impaired axonal transport.  Moreover, oxidative stress is associated with the development of 
13 
 
apoptosis in neurons and supporting glial cells and so could be the unifying mechanism that 
leads to nervous system damage in diabetes (Dorbretsov et al., 2007). 
 
1.5.3 Kidney 
The kidney prevents extra fluids accumulation, keeps the blood and electrolytes stable and it 
regulates the blood pressure. Kidney receives about 25% of the heart’s cardiac output 
(Brenner, 2001). Nephron is the main functional unit of the kidney (Cushman, 1980). 
Nephrons are about 0.6-1.4 x 106 which makes the kidney an efficient filtration organ 
(Brownlee, 2001). Nephron is made out of Bowman’s capsule, proximal convoluted tubule 
and distal convoluted tubules (Eroschenko). The glomerulus filters blood; it has got cells 
(podocytes) and mesangial cells which are responsible for blood filtration. Mesangial cells 
have phagocytic characteristics and they synthesize the extracellular matrix and secrets 
interleukin-1 (IL-1) and platelet derived growth factor (Rosenstock et al., 2010). It has been 
noted that during renal dysfunction podocytes fuse and lead to the formation of glomerular 
basement membrane (GBM) which is thick but leaky leading to proteinuria and glycosuria 
(Wolf and Ziyadeh 1999) . A prolonged renal dysfunction may lead to the total kidney failure 
hence dialysis or transplant is needed. 
 
1.5.3.1 Diabetic Nephropathy 
Diabetic nephropathy (DN), a frequent and major microvascular complication of diabetes 
mellitus, is the most common cause of end-stage renal failure disease (ESRD) diabetic 
patients (Sheetz and King, 2002).  DN is characterized by glomerular and tubules 
hypertrophy thickening of the basement membranes, accumulating of extracellular matrix 
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components, decrease in glomerular filtration rate (GFR), glomerulosclerosis as well as 
tubulo-interstitial fibrosis in mesangium and interstitium (Kanwar et al., 2008).  
 
Type 1 and type 2 diabetes mellitus can lead to DN (Mauer et al, 2001) (United States Renal 
Data System, 2010). From the year 1991-2001, the number of patients who start renal 
replacement therapy has doubled (US Renal Data System, 2010).  In the last decade there has 
been a dramatic increase in the proportion of ESRD patients affected by diabetes, and this 
increase is largely attributed to type 2 diabetes. The basic pathophysiology is similar in both 
type1 and type 2 diabetes mellitus patients. The natural course of DN is characterized by a 
mean rate of decline in GFR ranging from 25 - 0 ml/min/ year. Glomerular hyperfiltration is a 
characteristic of an early diabetic nephropathy in animal models of diabetes. Diabetes 
contributes to the production of prostaglandin which controls the vascular reactivity of the 
renal glomerular efferent arterioles allowing autoregulation of glomerular capillary pressure 
(Forbes et al., 2007). 
 
1.5.3.2 Pathogenesis of Diabetic Nephropathy (DN) 
Proximal tubules respond to different changes such as hypertrophy and ion transporters. 
Glucose enters the proximal tubules in an insulin dependent manner (Magri and Fava, 2009). 
In type 2 diabetes, there are comorbid factors such as metabolic syndrome and 
hyperinsulinemia and high blood pressure which are likely to affect DN, the most structural 
renal changes occur in the glomeruli whereas in type 2 diabetes several patients have more 
advanced tubulo-interstitial and vascular than glomerular lesions (Mauer et al., 2001 and 
Mauer et al., 1984). However, there are many similar pathological changes in the kidney in 
both type 1 and 2 diabetes.  
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During the early stages, DN is usually not seen at least for 3-5 years after diagnosis. A few 
changes can be noted at the initial stage such as increase in kidney size, enlarged glomeruli 
and supranormal glomerular filtration rate (HGFR). Ray et al., 1998 reported that the 
proximal tubule plays a role in kidney mass. Higher filtration rate of the kidney is due to 
increased blood flow and increased vascular permeability (Chiu et al., 2009). However, 
standard insulin treatment leads to reduction in renal size and an increase in GFR (Ditzel and 
Schwartz, 1967). 
In uncontrolled diabetes, the urinary albumin excretion is elevated. Early detection of DN 
could reverse or prevent long term outcomes hence preventing the development of ESRD. It 
is hypothesised that glomerular hypertension is due to provocation of the subsequent demise 
of diabetic kidney by the early hemodynamic genotype; this glomerular hypertension leads to 
glomerular hyperfiltration. In an early stage of DN there is an increase in reabsorption of 
electrolytes and fluids in type 1diabetes (Vallon et al., 2003). The proximal tubules 
reabsorption is enhanced due to the increased glomerular filtration of glucose which in turn 
increases proximal tubule reabsorption of Na+ and glucose through sodium glucose 
transporter proteins SGLT2 and SGLT1 (Vallon et al., 1999, and Vestri et al., 2001). 
 As diabetic nephropathy progresses, there is tubular growth which leads to renal damage, 
tubular growth due to inflammation resulting in increasing proteinuria, decline in 
glomerulosclerosis and tubulointerstitial (Anderson et al., 1988). GFR declines due to the 
small number of functioning glomeruli. At later stages, DN is characterised by the presence 
of persistent proteinuria and progressive decline in renal function, which results in renal 






1.6 Management and Current Treatment for Diabetes 
 At present, a number of hypoglycemic agents are popularly used to keep blood glucose in 
normal level such as exogenous insulin in type 1 diabetes. The short comings of insulin are 
that it cannot be given orally and it needs to be stored in the fridge, injection allergies and 
weight gain (Hirsch, 2005). Type 2 diabetes is managed by use of oral drugs which are 
hypoglycemic. They are divided into five classes; meglitidines; they stimulate the release of 
insulin from beta cells e.g. repaglinid and nateglide. Biguanides; they reduce hepatic glucose 
output and, to a lesser extent, enhance insulin sensitivity in hepatic and peripheral tissues e.g. 
metformin, thiazolidinedines; they enhance insulin sensitivity in both muscle and adipose 
tissue and to a lesser extent by inhibiting hepatic glucose production e.g. pioglitazone, 
troglitazone and rosiglitazone, α- glucosidase inhibitors; they act by inhibiting the enzyme 
alpha-glucosidase found in the brush border cells that line the small intestine, which cleaves 
more complex carbohydrates into sugars e.g. acarbose, miglitol and voglibose, 
sulfonylureas; they stimulate insulin release from the beta cells of the pancreas and may 
slightly improve insulin resistance in peripheral target tissues e.g. gilbenclamide, tolazamide, 
chlorpropamide, tolbumide and acetohexamide and (Hirsh, 2005). Incretins mimetics 
mimics incretins in the body. Incretins are hormones from glucagon superfamily released in 
response to nutrient ingestion by regulating the insulin secretory response to the products 
within the nutrients in the food.  Incretins mimetics lower blood sugar levels by preventing 
the pancreas from giving out too much glucagon e.g. exenatide and liraglutide. These drugs 
have no direct effect on DN. 
 
Diabetic nephropathy is managed by angiotensin converting enzymes (ACE) inhibitors. ACE 
inhibitors (ramipril and perindopril) control blood pressure and delay progression of kidney 
dysfunction. In humans, the rennin-angiotensin system plays a pivotal role in blood pressure 
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regulation and in the pathophysiology of cardiovascular diseases such as congestive heart 
failure and hypertension hence rennin-angiotensin system blockers also delays the 
progression of the ESRD (Erdos and Skidgel, 1987). Ramipril decreases the risk of overt 
nephropathy by 24% in type 2 patients (DIABHYCAR Study Investigators, 2004). Moreover, 
as blood pressure decreases, the cells of the juxtaglomerular apparatus release renin and 
activate the renin- angiotensin-aldosterone pathway. The juxtaglomerular apparatus is a small 
group of cells situated in the area where renal tubule links up with the efferent and afferent 
arterioles. Renin converts angiotensinogen into angiotensin I. Angiotensin converting 
enzymes (ACE) then converts angiotensin I into angiotensin II, a peptide hormone. 
Angiotensin II has one of its functions being stimulation of sodium reabsorption by the 
proximal convoluted tubules among others. These changes assist in restoring extracellular 
fluid volume and stabilizing blood pressure. ACE inhibitors are administered to block the 
production of angiotensin II in people with elevated blood pressure. Unexpectedly, these 
agents produce serious side effects in the clinical application, such as weight gain, 
gastrointestinal disturbances, edema, hypoglycemia and insulin resistance (Vasconcelos et 
al., 2001). 
1.7 Basis of the study 
Current treatment cannot arrest progression towards end stage renal disease (ESRD) (Lewis 
et al., 1993, Lewis et al., 2001 and Brenner et al., 2001). Hypoglycemic drugs present 
different approaches to control hyperglycemia in different types of diabetes, each with its 
own limitations and side-effects. Developing various means by which blood glucose can be 
effectively controlled while minimizing the iatrogenic side-effects remains a continuing task 





1.8 Medicinal plants used in diabetes management 
Medicinal plants have been successfully used by traditional healers to treat many diseases; 
they play a role in discovery of new therapeutic agents. A number of medicinal plants have 
been reported to have antidiabetic, antidyslipidemic, anti-inflammatory effects. Antioxidant 
activities of these medicinal plants have been evaluated and found to play a huge role in 
diabetes management due to their ability to reduce ROS generated by free radicals leading to 
superoxide and nitrogen oxides. The ROS affect the activity of glomerular filtration rate thus 
rendering it dysfunctional. Many plant extracts and products have been shown to possess 
significant antioxidant activity e.g. Phyllanthus emblica (Saleem et al., 2001) and Cichorium 
intybus (Ricci et al., 2006). Medicinal plants contain bioactive phytochemicals. They may 
have no nutritional value but are needed by the body because of their ability to prevent 
diseases (Wang et al., 2004). Phytochemicals such as alkaloids, sterols, triterpenes, phenolics, 




The flavonoids are a diverse group of polyphenolic compounds widely distributed in the plant 
kingdom. All flavonoids have a common basic structure (Figure 4). There are more than 6400 
known flavonoid compounds. In the grapefruit, flavonoids exist in the form of glycosides 
with naringin being the most abundant among others like narithrine, hesperidin and hesperitin 





Figure 3: Chemical structure of flavonoids Courtesy of Liu, RH, 2004 
 
Figure 4: Chemical structure of naringin (4′,5,7- trihydroxy flavonone 7-rhamnoglucoside). 
Courtesy of Shaddack, 2005. 
1.8.2 NARINGIN 
Naringin is the predominant flavonone found in grape fruits and related citrus species 
(Kawaii et al., 1999). Naringin has been reported to have antioxidant activities, free radicals 
scavenging properties (Seon et al., 2011) and it is the potent cholesterol lowering agent (Kim 
et al., 2006). Nevertheless, naringin and hesperidin exhibit anti-inflammatory and anti-
carcinogenic properties and hypoglycemic effects mediated by hepatic glucose regulating 
enzymes in C57BL/KsJ-db/db Mice (Jung et al., 2014). Punithavathi et al, (2008) reported 
that naringin combined with vitamin C ameliorates streptozotocin- induced diabetes in male 
Wister rats. Sharma et al, (2011) reported that naringin decreases insulin resistance, TNF-α 
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and IL-6 in type 2 diabetic rats and it increases adiponectin levels hence it ameliorates 
dyslipidemia and hyperinsulinemia. 
Naringin is also known to inhibit hepatic HMG-CoA reductase and ACAT enzymes which 
are involved in hepatic cholesterol biosynthesis thus improving atherogenic dyslipidemia in 
rats with type1 diabetes (Xulu and Owira et al., 2011). Similarly, it has been shown to exhibit 
antidiabetic and antioxidant effects in type 2 diabetic rats (Sharma et al., 2011). Currently it 
is not known whether reducing hyperglycemia-induced ROS could have beneficial effects on 
diabetes end-points. It is therefore hypothesized that naringin may prevent the progression of 
diabetic nephropathy by reversing or retarding the increased cellular concentration of ROS 
stimulated by hyperglycemia. This is expected to limit oxidative damage to the podocytes and 
arrest further deterioration to the kidney. Therefore, this study was set out to determine in 

















To investigate the effects of naringin on diabetic nephropathy rats in vivo with respect to: 
Objectives 
 developing an animal model of diabetic nephropathy. 
 serum and urine electrolytes.  





















                                              CHAPTER 2 
2.0 Materials and methods  
2.1 Chemical reagents and Equipments 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma Aldrich Pty. 
Ltd., Johannesburg, South Africa. Naringin, D-glucose, Streptozotocin, citrate, sodium 
sulphate, potassium hydroxide, potassium cyanide, butanol, ethanol, sulphuric acid, phenol, 
phosphate buffer, hydrochloric acid, phosphoric acid and glycogen were used in the study. 
Normal saline, insulin, glucometer and glucometer test strips (Ascensia Elite Bayer AG, 
Leverkusen, Germany) were purchased from a local pharmacy. 
 
2.2 Ethical Clearance 
The study was approved by the Animal Ethics Committee of the University of KwaZulu-
Natal, reference number 106/13/animal. 
 2.3 Procedure and animal treatment 
Male adult Wistar rats (Rattus novergicus, 200-300g body weight) were divided into 6 groups 
(n=7) and housed, 7 rats per cage, with free access to standard commercial chow and drinking 
tap water ad libitum. Female rats could not be used because they can be affected by hormonal 
changes during estrous cycle which might influence the outcome. The rats were maintained 
on a 12- hour dark to light cycle of 08.00 to 20.00 hours of light in an air controlled room 
(temperature 25 ± 2°C, humidity 55%) and were handled with human care according to the 
guidelines of the Animal Ethics Committee of the University of KwaZulu-Natal. 
Diabetes was induced in groups C, D, E and F (Table 1) by a single intraperitoneal injection 
of 60 mg/kg body weight (BW) of streptozotocin (STZ) dissolved in 0.2 ml of 0.1 ml citrate 
buffer, pH 4.5 after an overnight fast. Three days after administration of the STZ, 
development of diabetes was confirmed by tail pricking to analyse blood glucose levels. 
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Random glucose levels of less than 11mM were considered not diabetic and thus were 
excluded from the study. Group B and D were orally treated with 50 mg/kg/ BW of naringin. 
Group C was treated with regular insulin (4 U/kg/ BW) subcutaneously twice daily. Groups 
A and E were treated with 1.0 ml distilled water via gastric gavage. Group F was treated with 
20 mg/kg/ BW of ramapril. Blood glucose concentrations were measured once in two weeks 
by tail pricking and a portable glucometer was used to take the readings. Weight gain and 
water consumption were measured daily. Diabetic and non- diabetic animals were kept in 
metabolic cages individually and separately under feeding and metabolic control on day 55 
for 24 hours for urine collection. On treatment day 56, halothane overdose was used to 
sacrifice the rats and blood samples were collected by cardiac puncture for plasma insulin 
analysis. Kidneys and livers were excised after the animals were sacrifised, rinsed in normal 
















Table 1: Animal treatment schedule 
 
Groups 
                                           Treatment 
Distilled water    













A         +        _       _        _      _ 
B         _        _       +        _      _ 
C         _        +        _        +       _ 
D         _        +       +        _       _ 
E         +        +       _        _       _ 















2.4.1 Blood Glucose Determination  
Fasting blood glucose determinations were done on treatment days 0, 14, 21, 28, 56 
respectively; whereas oral glucose tolerance determination (GTT) was done on day 52. Blood 
glucose concentrations were determined after tail pricking and a portable glucometer was 
used to take the readings. Before GTT, the animals in all treatment groups were starved 
overnight and fasting blood glucose (FBG) concentrations were determined by administration 
of intraperitoneal injection of 3.0 mg/kg body weight of glucose in normal saline. Blood 
glucose concentrations were then measured at times 0, 15, 30, 60, 90 and 120 minutes in all 
treatment groups. Area under the curve (AUC) was calculated from blood glucose-time 
curves and presented as AUC units (millimoles per litre × minutes). 
 
2.4.2 Plasma Insulin quantification 
Plasma insulin levels were analysed by ultra-sensitive rat insulin enzyme-linked 
immunoassay kit (DRG Diagnostic Marburg Germany). Twenty five microliters (25 µl) of 
samples and 100 µl of enzyme conjugate were mixed in a 96-well microtiter plate, then 
incubated for 2 hours on a plate shaker at 900 rpm at room temperature (25ºC±2º). Seven 
hundred microliters (700 µl) of wash buffer was used to wash the plate 6 times and 200 µl of 
the substrate TMB was then added to each well and incubated at room temperature (25ºC±2º) 
for 15 minutes. Stop solution (50µl) was added to each well and incubated for 5 minutes on a 






2.4.3 Liver Glycogen assay according protocol. 
Hepatic glycogen content was measured by the method of Ong and Khoo (2000). The liver 
tissue (0.5 g) was placed in a test tube. One millilitre (1.0 ml) of 30% KOHw/ Na2SO4 was 
added in the tubes to enable homogenization and boiled at 100ºC for 20 minutes.  The tubes 
with foil (to avoid evaporation) were boiled for 30 minutes and then vortexed and allowed to 
cool in ice and 95% ethanol (2.0 ml) was added to the mixture to precipitate glycogen from 
alkaline digestate. The mixture was then incubated in ice for 30 minutes. The tubes were then 
centrifuged at 550 g for 30 minutes. The supernatant was carefully collected and the tubes 
were dried upside down for 5 minutes. Pellet was re-suspended in 1ml of distilled water and 
thoroughly vortexed and 1.0 ml of 5% phenol was then added to the mixture with the 
preparation being done in duplicates. Five millilitres (5.0 ml) of 98% sulphuric acid was then 
directly pippeted into the tubes content and the samples incubated on ice bath for 30 min. 
Three hundred millilitres (300 µl) from the tubes were pippeted to the microtiter plates and 
the optical density was read at 490 nm within 30 minutes using Spectrostar micro- plate 
reader. One millilitre (1.0 ml) of water was used as a blank. 
 
2.4.4 Thiobarbituric acid-reactive substances (TARBS) Assay in renal tissue 
Phulukdaree Chuturgoon AA (2010) protocol. 
Plasma TBARS assay was carried out as previously described by Phulukdaree Chuturgoon  
(2010). Renal cortex (100 mg) was homogenized in 450 µl of 0.2% phosphoric acid (H3PO4) 
and centrifuged at 1000 x g for 10 minutes at 4ºC. The supernatant was then collected; 200 µl 
of 7% phosphoric acid (H3PO4) and 400 µ of BHT/TBA solution was added as well as 100 µl 
of 1M HCL. The solution was incubated in boiling water bath (100ºC) for 15 minutes and 
later on cooled at room temperature (25±2). Butanol (1.5ml) was then added to all the tubes 
and they were thoroughly vortexed before 200 µl of the top phase of the solution was then 
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transferred to a 96 well microplate in triplicates. The absorbance was read at 532 nm and 600 
nm using a Spectrostar micro-plate reader. The kidney MDA was calculated using the 
formula below.  
 
     Concentration = A532− A600
156Mm⁻¹
 
                   
2.4.5 Superoxide Dismutase Assay 
SOD activity of the renal tissue (mitochondrial) was measured using commercially available 
kit. The tissue was homogenized at 10,000 x g in 5 ml cold buffer for 15 minutes at 4ºC and 
the supernatant (upper layer) was discarded; the pellet was used.  Potassium cyanide (1 mM) 
was added to inhibit other enzymes (Cu/Zn-SOD) and extracellular SOD. Radical detector 
(200 µl) was pipetted to each well of a microtiter plate and 10 µl of sample was then added. 
To initiate the reaction, 20 µl of diluted xanthine oxidase was added as quickly as possible to 
all wells. 96 -well plate was shaken carefully and incubated on the shaker for 20 minutes at 
room temperature (25±2º). The activity of SOD was calculated as the amount of SOD that 
produces a 50% dismutation of superoxide ion by reading absorbance at 450 nm by 
Spectrostar, micro-plate reader. 
2.4.6 Urine and serum electrolytes analysis 
The samples were removed from the freezer and thawed at room temperature for analysis of 
electrolytes. Briefly, 40 ml of samples were mixed with a buffered solution. The ratio used 
was one part sample to 33 parts buffer (1:33). The higher molar strength buffer was added. 
Electrolytes sodium (Na+), potassium (K+) and chloride (Cl-) constant coefficients were 




2.4.7 Glomerular filtration rate (GFR) 
The urinary clearance of creatinine and plasma creatinine were used to calculate the 
glomerular filtration rate using the formula below: 
Creatinine clearance (ml/min ) 
 urinary creatinine 
Plasma creatinine 
mmol/L x urine volume (ml) 
2.4.8 Statistical analysis 
All data were presented as means ± standard error of mean (SEM). Statistical comparisons in 
different groups were performed by using One Way Analysis of Variances (ANOVA) and 
student t test. All statistical analysis were performed with Graph-pad InStat Software (version 
5, GraphPad Software, San Diego, California USA). A value of p<0.05 was considered 


















3.1 Weight gain  
Untreated diabetic group exhibited significant (p<0.001) weight loss compared to the normal 
control groups (Figure 5) however, diabetic rat groups that were treated with naringin and 
insulin significantly improved weight gain (p<0.001) compared to the diabetic control group. 



































Figure 5: The animal weights were recorded at baseline and at the end of the treatment period 
and the differences were recorded as means per treatment group as an indication of growth. C 
(normal control), N (normal naringin), INS-D (diabetic mellitus and insulin), NAR-D 
(diabetic naringin), D (diabetic mellitus), RAM-D (diabetic ramapril). ***p<0.001 compared 






3.2 Water consumption 
The average daily water consumption was consistently and significantly (p< 0.001) higher in 
all diabetic rats compared to normal control groups (Figure 6). However, polydipsia was 
significantly (p<0.05) less pronounced in the naringin, ramapril and insulin treated groups 
compared to the non-treated diabetic rats, respectively (Figure 6). 
 
 
Figure 6: Water consumption in ml was recorded by measuring the volume of water in the 
drinking bottle each morning before a fresh one was added. (C (normal control), N (normal 
naringin), INS-D (diabetic mellitus and insulin), NAR-D (diabetic naringin), D (diabetic 
mellitus), RAM-D (diabetic ramapril). Dp<0.001 compared to normal control and 
































3.3 Urinary output 
Urinary output was significantly higher (p<0.001) in diabetic rats compared to normal control 
groups but the treatment with insulin and ramapril significantly (p<0.05) reduced urine output 
compared to the non-treated diabetic rats. Naringin did not significantly reduce the urinary 
































Figure 7: Urinary output C (normal control), N (normal naringin), INS-D (diabetic mellitus 
and insulin), NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic ramapril). 











3.4 Fasting blood glucose 
Diabetic rats had elevated fasting blood glucose (p<0.001) (from day 14-56) compared to the 
normal controls however, the treatment with naringin, insulin and ramipril significantly 




























Figure 8: Fasting blood glucose C (normal control), N (normal naringin), INS-D (diabetic 
mellitus and insulin), NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic 









3.5 GTT and Area under the curve  
The effect of naringin was evaluated by GTT on overnight fasted animals. Diabetic groups 
showed glucose intolerance compared to normal controls (p<0.001). Naringin or insulin 
treatment did not improve glucose intolerance compared to diabetic control (Figure 9A) and 
area under the curve was calculated from OGTT (Figure 9B). 
 


























































Figure 9: OGTT and Area under the curve. Ramipril treated group had blood glucose which 
was above what the glucometer could measure (>33.3mmol/L). C (normal control), N 
(normal naringin), INS-D (diabetic mellitus and insulin), NAR-D (diabetic naringin), D 












3.6 Fasting plasma insulin 
The fasting plasma insulin was significantly lower (p<0.001) in diabetic groups compared to 
normal controls. Treatment with naringin or insulin improved plasma insulin secretion in 
both diabetic and normal rats. Ramapril did not significantly improve plasma insulin 
































Figure 10: Fasting plasma insulin C (normal control), N (normal naringin), INS-D (diabetic 
mellitus and insulin), NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic 
ramapril). ***p<0.001 and *p<0.05 compared to normal control, and #p<0.001compared to 








3.7 Hepatic glycogen 
The diabetic groups had a significantly (p<0.001) reduced hepatic glycogen content 
compared to the non-treated diabetic control group. However, treatment with insulin or 
naringin significantly (p<0.01 and p<0.05) increased hepatic glycogen content as compared 
to the non-treated diabetic control respectively. Ramipril did not significantly increase 



























Figure 11: Hepatic glycogen C (normal control), N (normal naringin), INS-D (diabetic 
mellitus and insulin), NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic 









3.8 Lipid peroxidation 
MDA concentrations in the kidney were elevated in diabetic groups when compared with 
normal controls but were significantly reduced (p<0.05 and p<0.01) when treated with 






































Figure 12: Lipid peroxidation C (normal control), N (normal naringin), INS-D (diabetic 
mellitus and insulin), NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic 









3.9 Superoxide Dismutase 
Diabetic rats had significantly (p<0.001) reduced activities of SOD compared to normal 
controls however, chronic treatment with naringin, insulin or ramipril significantly (p<0.01, 



































Figure 13: Lipid peroxidation C (normal control), N (normal naringin), INS-D (diabetic 
mellitus and insulin), NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic 









3. 10 Urine biomarkers 
Electrolytes (Na+, K+ and Cl-), urea and creatinine levels were significantly (p<0.001) 
decreased in the urine of diabetic groups compared to normal controls however, naringin or 
insulin significantly (p<0.05) reversed sodium and potassium retention compared to diabetic 
control (Figures 14A and B). Naringin showed no effect on urinary chloride and urea 
(Figures 14 C & D). Treatment with naringin, insulin or ramipril significantly (p<0.001) 



































































































































































Figure 14: Urine electrolytes A (sodium), B (potassium), C (chloride), D (urea) and E 
(creatinine) C (normal control), N (normal naringin), INS-D (diabetic mellitus and insulin), 
NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic ramapril)***p<0.001 










3.11 Serum electrolytes  
Serum electrolytes were similar between diabetic rats and normal controls however, serum 
creatinine of diabetic group was significantly higher (p<0.04) compared to normal control 






























































































































3.12 Glomerular Filtration Rate (GFR) 
GFR was calculated using the formula in 2.4.7. In STZ-induced groups GFR was 
significantly (p<0.001) decreased compared to normal control groups however chronic 
treatment with naringin, insulin and ramipril significantly (p<0.05) increased glomerular 
filtration rate (Table 5). 
Table 2: Showing expressed mean ± of treatment(s) against Creatinine and urinary output in 










Urinary output (ml) 
 










































































Figure 16: GFR C (normal control), N (normal naringin), INS-D (diabetic mellitus and 
insulin), NAR-D (diabetic naringin), D (diabetic mellitus), RAM-D (diabetic ramapril) 













4.0 Discussion  
Type1 diabetes is characterized by low insulin due to predisposition to cell autoimmunity and 
it is associated with high blood glucose, low insulin, weight loss, polydipsia and polyuria. In 
order to induce diabetes in this study; beta cells were destroyed by using (STZ). Low doses 
(40 mg/kg) of STZ destroy the pancreatic beta cells partially but the rats become diabetic 
permanently (Aybar et al., 2001). Using 60 mg/kg of STZ destroy beta cells completely 
leading to clinical diabetes within 2-4 days (Weiss et al., 1982). Streptozotocin selectively 
destroys pancreatic beta cells by inducing toxicitity by DNA alkylating activity and induction 
of free radicals production (Nukatsuka et al., 1990 and Yamamoto et al., 1981). In the present 
study, Type1 diabetes mellitus model was successfully created after 3 days of diabetes 
induction; elevated blood glucose, polydipsia, polyuria and weight loss that indicated 
deficiency of insulin biosynthesis and secretion in Wister rats. 
In type 1 diabetes low insulin or infectiveness leads to drop in body weight since it is an 
anabolic hormone; Low insulin leads to elevation of counter regulatory hormones; glucagon, 
cortisol, growth hormone and catetholimines. These hormones are catabolic and contribute to 
weight loss. Elevation of these hormones results in lipolysis and production of ketone bodies 
(Gerich et al., 1996). These hormones activate hormone sensitive lipase in the adipose tissue 
which in turn causes breakdown of triglyceride into glycerol and free fatty acids. In this 
study, weight loss was pronounced in diabetic rats compared to normal groups (p<0.001) 
(Figure 5). However, naringin improved weight loss (p<0.05) which means naringin through 
its known antioxidant and free radical scavenging effects could have inhibited the release of 
counter regulatory hormones as reported by Kitabchi et al., (2001) that reactive oxygen 
species are involved in the provocation of counter regulatory hormones. Weight loss in 
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untreated type 1 diabetes is also due to the inability of cells to utilize glucose for energy 
production, but rather there is a remarkable activation of the gluconeogenic pathway. The 
excessive utilization of muscle protein and excessive mobilization of fats from the adipose 
tissues for energy production in the gluconeogenic pathway accounts for the weight loss in 
type 1 diabetes. Also frequent episodes of urinating (polyuria) due to hyperglycemia result in 
dehydration are possible cause of weight loss.   
In this study, water consumption was significantly higher in diabetic rats compared to the 
normal controls (Table 3). Hyperglycemia changes the blood osmotic potential and the 
receptor in the hypothalamus reacts to the shift in osmotic pressure and triggers dehydration 
and electrolytes disturbances. Interestingly, diabetic groups treated with naringin significantly 
reduced polydipsia (p<0.001) compared to diabetic control. Similarly ramipril reduced 
polydipsia (Figure 6) and urine output (Figure 7) which was expected because ramipril is 
known to have reno-protective effects; however, naringin did not reduce urine output which 
could mean naringin does not have antidiuretic effects. In DM, the renal threshold (11mM) 
for glucose is exceeded (i.e. plasma glucose concentration is above the normal range) and 
glucose is excreted in the urine.  Glucose then acts as osmotic solute in the urine, producing 
an osmotic diuresis (polyuria).  
 
4.1 Effects of naringin on glucose homeostasis 
Individuals with DM have hyperglycemia due to lack of insulin hence glucose accumulates in 
bloodstream due to decreased uptake by skeletal muscles. In this study fasting blood glucose 
was significantly elevated in diabetic groups compared to normal controls suggesting 
hyperglycemia and insulin deficiency (Figure 8). However, naringin reduced fasting blood 
glucose and did not improve glucose intolerance suggesting that naringin might require 
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insulin to exhibit its hypoglycemic effects just like metformin (Pari, 2010). Metformin is a 
biguanide that activates adenosine monophosphate- activated protein kinase (AMPK). AMPK 
is a multisubunit enzyme that is recognized as a major regulator of lipid biosynthetic 
pathways due to its role in the phosphorylation and inactivation of key enzymes such as 
acetyl-CoA carboxylase and it also regulates  expression of cAMP-stimulated gluconeogenic 
genes such as PEPCK and G6Pase (Lochhead et al., 2000). In the previous study in our lab, it 
was reported that naringin does not ameliorate hyperglycemia in type 1 diabetes (Xulu, 
Owira, 2012).  Conversely, naringin improved insulin secretion in normal rats and diabetic 
rats compared to normal control. This therefore means that naringin functions through its free 
radical scavenging activities to boost mitochondrial antioxidant capacity leading to the 
increase of ATP production ultimately insulin secretion. Previous studies (Pari and Suman, 
2010, Jung et al., 2004 and Heart et al., 2012) reported that naringin improves plasma insulin 
secretion which is consistent with our findings (Figure 10). In diabetic state there is an 
increase in hepatic glucose production and decreased hepatic glycogen synthesis which might 
be due to decreased activity of glucokinase ultimately glycolysis (Felig and McGarry et al., 
1992).  Glucokinase is an enzyme that acts as a glucose sensor, facilitates phosphorylation of 
glucose to glucose-6-phosphatase. In the current study hepatic glycogen was significantly 
decreased in diabetic groups (p<0.001) (Figure 11). However, treatment with insulin and 
naringin significantly (p<0.01 and p<0.05) increased hepatic glycogen respectively. This is 
supported by Punithavathi et al., (2008), who reported that naringin increased hepatic 
glycogen storage by regulating gluconeogenesis by lowering the activities of glucose-6-
phosphatase and PEPCK. The increase in hepatic glycogen storage may improve the 





4.2 Effects of naringin on oxidative stress 
Sustained hyperglycemia is associated with alterations in oxidation state due to the increase 
in production of reactive oxygen species (ROS) and the reduction of antioxidant 
concentrations. Wang et al, (2011) reported that oxidative stress contributes to the 
relationship between acute hyperglycemia and its complications including nephropathy 
(Lehmann and Schleicher, 2000). Oxidative stress induces the expression of tubular growth 
factors, tumor necrosis factors, interleukins (1, 6 and 18) and vascular endothelial growth 
factors which give rise to extracellular matrix proteins and promote glomerular and tubular 
fibrogenesis. Vascular endothelial growth factors are primarily involved in neoangiogenesis 
and increased endothelial permeability due to apoptosis of podocytes. Apoptosis of the cells 
might contribute to the structural changes that occur in the diabetic kidney which lead to the 
formation of glomerular basement membrane becoming leaky leading to proteinuria 
ultimately total kidney failure (Wolf and Ziyadeh 1999).  
 
Thiobarbituric acid reactive substance (TBARS) is a biomarker for oxidative stress; it 
measures lipid peroxidation which is induced by increased free radicals. Lipid peroxidation is 
higher in patients with diabetic nephropathy (Griesmacher et al., 1995; Kedziora-
Kornatowska et al., 1998). Lipid peroxides can stimulate prostaglandin production, which is a 
well-recognized source of free radicals. Prostaglandins also alter renal hemodynamics in 
various stages of diabetic nephropathy (Salahudeen et al., 1997). In this study, diabetic rats 
exhibited higher lipid peroxidation (p<0.001) compared to non-diabetic controls, suggesting 
increased oxidative stress (Figure 12). Interestingly, naringin significantly reduced (p<0.05) 
renal lipid peroxidation in diabetic rats compared to normal controls. Naringin has been 
previously reported by Sharma et al., (2011) to have antioxidant activities and free radicals 
scavenging properties which may decrease the cell viability through suppressing the 
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excessive production of ROS in the kidney. Moreover, natural antioxidants (enzymatic and 
non-enzymatic) are expected to prevent damage by reducing reactive oxygen species. 
MnSOD was significantly reduced in diabetic groups suggesting the increase in oxidative 
stress (Figure 13). This is supported by other studies which reported that in diabetic state both 
types of antioxidants are supressed by AGEs (Arali et al., 1997). However chronic naringin 
treatment significantly increased the activity of mitochondrial superoxide dismutase (Figure 
13). These results then indicate that naringin acts as a superoxide scavenger and an 
antioxidant just as it has been previously reported (Sharma et al., 2011). Ramipril and insulin 
showed similar effects as naringin (p<0.05 and p<0.001) respectively. ACE inhibitors are 
currently used to treat diabetic nephropathy; they reduce the circulating angiotensin II. Ang II 
is involved in reactive oxygen species production by activating NADPH oxidase, an enzyme 
known to be overactive in diabetes, hence contributing to the increased oxidative stress in 
renal tissue. 
 
4.3 Effects of naringin on renal function  
Sustained hyperglycemia leads to renal dysfunction such as proteinuria, imbalance in 
electrolytes and fluids, reduction in GFR and elevated blood pressure (Magri and Flava, 
2009) which lead to renal failure. Hannedouche et al (1990) have previously reported that 
there is electrolyte retention (Na+, K+ and Cl-) in insulin-dependent diabetes mellitus in 
experimental animals. Retention of Na+ in proximal tubules is associated with decreased GFR 
via sodium/glucose transporter (Vallon et al., 1999). Na+ and glucose are transported by 
SLGT2 in the proximal tubules in concert with facilitative glucose transporters (GLUTs) 
(Chao and Henry, 2010). SGLT2 has been detected in high levels in the renal cortex of a 
diabetic rat and is described as the major Na+/glucose cotransporter in the kidney 
(Rosenstock et al., 2010). Glucose efflux from the tubules relies on the gradient created by 
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Na+- dependent influx due to outwardly directed glucose gradient. About 90% of plasma 
glucose is filtered in the glomerulus of the kidney and is reabsorbed by SGLTs (symporters) 
in the proximal tubules of the kidney. In this study, retention of electrolytes was increased in 
diabetic rats, this was confirmed by the low levels of electrolytes in urine (Figure 14 A, B and 
C) suggesting hyperkalaemia and hypernatremia in diabetic rats (Hannedouche et al., 1990). 
It is noteworthy that naringin led to the increase in levels of electrolytes in urine (Figure 14). 
Naringenin (naringin aglycones) has been reported to have inhibitory effects on renal and 
intestinal SLGTs (Jian et al., 2005). 
 
Na+ handling is very important in understating renal function as it is a major electrolyte that 
controls osmolality in blood and, therefore extracellular fluid (ECF) volume. Na+ retention is 
associated with low GFR (Vallon et al., 1999). Rebsomen et al (2006) reported that 
glomerular filtration rate (GFR) and creatinine clearance (CrCl) are good markers for renal 
function, they measure how well the kidneys filter the DN-induced build-up of blood 
creatinine.   In this study glomerular filtration rate was significantly reduced (p<0.001) in 
STZ-induced diabetic rats compared to normal controls, interestingly treatment with naringin 
significantly increased GFR compared to diabetic control (Figure 16). Ramipril showed 
similar effects as naringin as expected. Renal impairment is suspected to be due to the 
hyperfiltration rate during early stages of the disease. However, as the disease progresses, 
renal function deteriorates and GFR declines drastically (Rudberg et al., 1997; Mogensen, 
1997). Hyperglycemia causes osmotic diuresis that leads to hypovolemia and decreased 
glomerular filtration rate. Moreover, chronic exposure to hyperglycemia is associated with 
decrease in urine urea and creatinine. Urea and creatinine are waste products which are 
normally excreted by the kidneys in urine; however, in diabetic state there is low clearance 
hence they accumulate in blood and hence their low concentration in urine (Lau et al., 2007). 
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Low urine creatinine and urea levels were observed in this study in diabetic rats and high 
levels in serum (Figure 14 E and 15 D). Naringin however, significantly improved creatinine 



























These results demonstrate that in the diabetic nephropathy model created diabetic state is 
characterised by hyperglycemia, polyuria, polydipsia, weight loss, low insulin, reduced 
glomerular filtration rate and electrolytes disturbances. However, naringin improved renal 
function in diabetic rats through increased GFR and urinary electrolytes output despite not 
improving glucose intolerance. This suggests that naringin exhibits reno-protective effects 
independently of glucose hemeostatis in diabetic rats by reversing oxidative stress associated 
with DN. These results therefore suggest that naringin supplementation could have positive 
implications to diabetic end-points such as DN. 
 
5.2 Limitations of the study 
Histology and glucose concentrations in urine were not measured and renal regulating 
hormones like aldosterone were not measured to relate the effects of naringin on renal tissue 
with biological functioning of hormones. 
 
5.3 Recommendations 
Future studies should investigate  
 The effect of naringin on Na+/glucose transporters (STLGs) expression in the kidney 
and urine glucose. 
 Hormones (aldosterone and vasopressin) should be measured. 
 Structural changes associated with DN should be evaluated in the in the presence of 
naringin supplemental in diabetic state 
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